65,437 trials
Lung Non-Small Cell Carcinoma · Stage I Lung Cancer AJCC v8 · Stage IA1 Lung Cancer AJCC v8
Primary: 6-month CT Assessment (Tumor Response Per mRECIST) — 1; 36; 2; 1 Participants
HIV Infections · Pregnancy Related
Primary: Maximum Observed Plasma Concentration (Cmax) of Doraviraine During Pregnancy — 1340; 928; 1060; 252 ng/mL — p=0.400
Rotator Cuff
Primary: Clinical Success Rate at 6 Months — 58; 68 Participants
Respiratory Syncytial Virus Infections
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs), Treatment-emergent Serious Adverse Events (TESAEs), Adverse Events of Special Interest (AESIs)…
Chronic Hepatitis B
Primary: Number of Subjects With Adverse Events as Assessed by CTCAE v5.0 — 9; 13; 3; 16 Participants
Hiv
Primary: M:P Ratio — 0.26; 0.0085 ratio
Leber Hereditary Optic Neuropathy
Primary: Change From Baseline of the Best Corrected Visual Acuity (BCVA) Reported With Log of the Minimal Angle of Resolution (LogMAR) at 1.5 Years Post-treatment, in the Second…
Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8 · Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8
Primary: Pain-reduction Effects of Adding Venlafaxine to a Regimen of Gabapentin and Methadone to Control Pain During and After Chemoradiation — 8; 13; 39; 40 scores on a scale
Type 2 Diabetes Treated With Insulin
Primary: Primary Safety Endpoint - Change in HbA1c Phase 1 — -0.71 Percentage of HbA1c — p=<0.0001
Colorectal Cancer
Primary: Overall Survival — 175.0; 169.0 Days — p=0.0021
Mental Health
Primary: Inventory of Psychosocial Functioning (IPF) — 32.60; 32.69; 33.51; 29.30 score on a scale
Tinnitus, Subjective · Tinnitus
Primary: Tinnitus Functional Index (TFI) — -12.1; -12.4; -6.0 scores on a scale
Insomnia · Metabolic Health · Menopause
Primary: Change From Baseline in Insomnia Severity Index (ISI) Score at 4 Weeks — 14.6; 14.5; -5.8; -2.7 units on a scale — p=0.04
Pancreatic Adenocarcinoma
Primary: Survival in Patients With Pancreatic Adenocarcinoma According to Tissue microRNA Expression — 8.3 months
Hyperlipidemias
Primary: Percent Change in LDL Cholesterol From Baseline to 12 Months — -46.6 Percent (%)